Fagron reports 10.3% revenue growth in first quarter

Fagron reported Q1 revenue of €263.4m, up 10.3% YoY, with organic growth of 3.2% at constant FX and Latin America delivering 10.4% organic growth. The company completed the acquisition of Pharmavit (Netherlands), which supported revenue and is integrating as planned. For fiscal 2026 Fagron guides mid- to high-single-digit organic sales growth at constant FX and targets a REBITDA margin of ~20%, expecting acceleration from Q2 and stronger H2 performance.

Analysis

The company is running a playbook of buy-and-integrate plus regional brand rollouts, which creates a two-source margin upside: procurement/scale synergies from tuck-ins and higher-margin mix from branded compounding in underpenetrated EM markets. Expect the procurement lever to produce low-hanging cost savings (think mid-hundreds of bps if manufacturing and API sourcing are consolidated) within 12–18 months, while mix-driven margin expansion is inherently slower and tied to brand traction and reimbursement cycles.

Emerging-market concentration materially changes the risk profile versus a pure EU compounding peer. FX volatility, local reimbursement shifts, and slower receivables conversion can create P&L noise for 2–4 quarters even if underlying demand remains intact; conversely, a benign FX path and tighter working capital could meaningfully amplify free cash flow in the back half of the year. Monitor country-level inventory and DSO trends as leading indicators of sustainable margin conversion.

Primary downside is operational: integration mis-execution or a compounding-quality regulatory event would reverse sentiment quickly and compress multiples by multiple turns given the business’s reliance on trust and scale. On the upside, successful integration plus incremental tuck-ins could create optionality for faster M&A roll-ups, allowing the firm to re-rate toward specialty CMO/compounding peers over 6–24 months if management converts revenue growth into stable, above-market REBITDA margins.

Key Decisions for Investors

• Long equity (ticker: FAGRO) — 6–12 month horizon. Size as a tactical overweight (3–5% of small-ideas sleeve). Target +30–50% upside from multiple expansion if integration synergies materialize; hard stop -20% on integration/margin misses or any regulatory quality notice.
• 12-month call spread (buy ATM, sell 20% OTM) on FAGRO — defined-cost long with ~2–3x upside if stock rallies >20% while capping premium outlay. Use as a leveraged, capital-efficient way to play H2 operational cadence without open-ended downside.
• Relative-value pair: long FAGRO / short LONN.SW (Lonza) — 6–12 months. Isolates compounding/EM brand upside vs commodity CMO exposure; target spread tightening equivalent to ~300–500bps REBITDA advantage. Keep 1:1 notional and trim if Lonza outperforms by >15%.
• Protective put spread on FAGRO (6–9 months) — buy modest downside protection (e.g., 15%/30% put spread) financed with selling deeper OTM puts. Cost-effective hedge against integration failure or a regulatory recall that would drive >30% drawdown.